Clinical Trial Update: A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols [Phase 3]

View source ↗

Summary

Phase 3 study of Pegasys (pegylated interferon alfa-2a) with or without ribavirin in chronic hepatitis C patients who previously participated in Roche protocols…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 3 | Status: COMPLETED | Results posted: 2013-09-13